Literature DB >> 8403546

Activation of human neutrophils and monocytes induced by immune complexes prepared with cationized antibodies or antigens.

J R Geffner1, A S Trevani, M Schatner, E Malchiodi, D H López, M Lazzari, M A Isturiz.   

Abstract

We have recently showed that soluble immune complexes (IC) prepared with cationic antibodies (catIC) induce high levels of neutrophil-mediated cytotoxicity against nonsensitized target cells. In the present work we extended our previous findings by studying the ability of catIC to induce different responses mediated by monocytes and/or neutrophils: monocyte cytotoxicity against nonsensitized target cells, chemiluminescence emission by monocytes and neutrophils, and elastase release from neutrophils. Our results showed that, in all cases, cell responses induced by catIC were markedly higher than those induced by control IC, indicating that cationized antibodies enhance IC ability to trigger phagocytic cell activation. A second aim of the present study was to analyze the effect of antigen cationization on IC properties. Interestingly, we found that all the phagocytic cell responses induced by IC prepared with cationized ovalbumin (OA) were significantly higher than those induced by IC prepared with untreated OA. Our results suggest that the charge of antibody and/or antigen constitutes a critical property that conditions the biological activity of IC. Furthermore, these findings support an important role of cationic antibodies and antigens in the development of inflammatory events associated with certain IC-induced diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403546     DOI: 10.1006/clin.1993.1143

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  1 in total

1.  Influence of the electric charge of the antigen and the immune complex (IC) lattice on the IC activation of human complement.

Authors:  M A Michelin; L S P Crott; A I Assis-Pandochi; T M Coimbra; J E Teixeira; J E Barbosa
Journal:  Int J Exp Pathol       Date:  2002-04       Impact factor: 1.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.